enGene Therapeutics Inc. (ENGN) Q3 2024 Earnings

ENGN·Reported September 10, 2024·Before market open

Diluted EPS came in at $-0.32, beat the $-0.37 consensus by $0.05.

Diluted EPS

$-0.32beat by $0.05

Consensus: $-0.37

SEC Filings

Earnings release8-K not filed yet

Quarterly report10-Q · 0000950170-24-105180

Financial Snapshot

Trailing eight quarters through Q3 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q3 2024 Earnings FAQ

Common questions about enGene Therapeutics Inc. 's Q3 2024 earnings report.

enGene Therapeutics Inc. (ENGN) reported Q3 2024 earnings on September 10, 2024 before market open.

enGene Therapeutics Inc. reported diluted EPS of $-0.32 for Q3 2024.

EPS beat the consensus estimate of $-0.37 by $0.05.

You can read the 10-Q periodic report (0000950170-24-105180) directly on SEC EDGAR. The filing index links above go to sec.gov.